Index Entries

Kevin McKernan, Anthony M. Kyriakopoulos, and Peter A. McCullough
November 24, 2021

Conclusions

The argument that the spike proteins synthesized by codon optimized mRNAs are identical to spike protein from the virus should be cautiously examined. There are several arguments that challenge this dogma. First, the biodistribution of non-specific LNP [lipid nanoparticle] transfection of mRNAs does not discriminate towards ACE2 or CD147 expressing cell lines as seen with the virus. Second, the mRNA that encodes spike protein is known to be different in several regards... Additionally, the expression levels and duration of these mRNAs may be longer and of higher copy number in many tissues that never experience natural virus infection... Finally, the pharmacokinetics of injection are different than infection. 30ug- 100ug per injection (90ug-300ug for those boosted) of Spike mRNA equates to 13 Trillion to 40 Trillion mRNA molecules injected in a few seconds with each injection. The pharmacokinetics of this bolus injection differs from that of viral replication that occurs over the course of a few days. If each of these mRNAs can produce 10-100 spike proteins and you have 30-40 Trillion cells, there may be a far greater systemic quantity and a much longer duration of spike protein exposure through the vaccination route than natural infection. Boosters given more frequently than a year will lead to total body accumulation of spike protein and further heighten the risk of disease in organs such as the brain, heart, bone marrow, and immune cells and tissues. This false equivalency may lead to an under appreciation of the symptomatology of vaccine based adverse events."

document
COVID-19,mRNA,SARS-CoV-2 spike protein,vaccine biodistribution,vaccine dynamics,vaccines